Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
DGRW vs XBI: how they differ
DGRW and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
WisdomTree U.S. Quality Dividend Growth Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, DGRW and XBI hold 0% of their money in the same securities at the same weight.
| Only in DGRW | Only in XBI |
|---|---|
| NVIDIA CORP 7.95% | MODERNA INC 2.87% |
| MICROSOFT CORP 5.75% | TWIST BIOSCIENCE CORP 1.81% |
| APPLE INC 3.87% | HALOZYME THERAPEUTICS INC 1.47% |
| META PLATFORMS INC 2.97% | NATERA INC 1.46% |
| UNITEDHEALTH GROUP INC 2.92% | KYMERA THERAPEUTICS INC 1.45% |
| COCA-COLA COMPANY (THE) 2.88% | TRAVERE THERAPEUTICS INC 1.40% |
| HOME DEPOT INC (THE) 2.81% | ROIVANT SCIENCES LTD 1.39% |
| JOHNSON & JOHNSON 2.34% | ORUKA THERAPEUTICS INC 1.38% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and Sep 10, 2026.
| DGRW WisdomTree U.S. Quality Dividend Growth Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | WisdomTree | State Street |
| What it is | U.S. Quality Dividend Growth | SPDR S&P Biotech |
| Total return, 1 year | +12.4% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −5.1 pts | +46.5 pts |
| Expense ratio | 0.28% | 0.35% |
| Already in the S&P 500 | 96.7% | 8.5% |
| Holdings | 197 | 154 |
DGRW in plain words
DGRW is an index equity fund tracking the U.S. Quality Dividend Growth. Over the year to Sep 11, 2026 it returned +12.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.28% a year. By its holdings filed for Jun 30, 2026, 97% of the fund by weight is stocks the S&P 500 also holds, across 197 positions, with the top ten at 36.2%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, DGRW or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, DGRW returned +12.4% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, DGRW or XBI?
- DGRW charges 0.28% a year and XBI charges 0.35%, so DGRW is cheaper. Fees come from each fund's prospectus.
- How much do DGRW and XBI overlap with the S&P 500?
- By their latest filed holdings, 97% of DGRW and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, DGRW against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/dgrw-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources